A novel PNPLA6 compound heterozygous mutation identified in a Chinese patient with Boucher‑Neuhäuser syndrome

Introduction

Boucher-Neuhäuser syndrome [BNS; Mendelian Inheritance in Man (MIM) reference no. 215470; www.omim.org] is a rare autosomal recessive disorder and is characterized by spinocerebellar ataxia, eye abnormalities and a failure of the pituitary gland to stimulate gonadal development during puberty (1–8). Previously, mutations in patatin-like phospholipase domain containing 6 (PNPLA6) have been linked to BNS (9–13). PNPLA6 (MIM reference no. 603197; www.omim.org; 19p13.2) encodes for a neuropathy target esterase (13,14). A total of five different transcripts have been identified, with the longest transcript, transcript variant 1 (GenBank accession no. NM_001166111.1; www.ncbi.nlm.nih.gov/genbank), encoding a protein (GenBank accession no. NP_001159583.1) of 1,375 amino acids (14). In addition to BNS, variations in the PNPLA6 gene have been implicated in Gordon Holmes syndrome, spastic paraplegia, photoreceptor degeneration and pure cerebellar ataxia (12,15–17).

Hypogonadotropic hypogonadism may be identified at the onset of puberty (18–20). Gait ataxia in BNS generally manifests prior to early adulthood, although late-onset ataxia has additionally been reported (2,9). In the present study, a 39-year-old male was initially diagnosed with hypogonadotropic hypogonadism at the age of 14 years. Subsequent magnetic resonance imaging (MRI) and funduscopic examination suggested that the symptoms were a result of BNS. The cause of the symptoms was further confirmed by the presence of a compound heterozygous PNPLA6 mutation.

Materials and methods

Patients

The proband and his parents were recruited at the People's Hospital of Henan Province (Zhengzhou, China) in March 2016. The age range of patients was 39–70 years old. Written informed consent was obtained. The present study was approved by the ethics committees of Central South University and The People's Hospital of Henan Province.

Clinical assessments

Endocrine manifestation in serum isolated from whole blood samples (1 ml per patient) were examined using the following ELISA kits: Human luteinizing hormone ELISA kit (cat. no. ab108651; Abcam, Cambridge, UK), human follicle stimulating hormone ELISA kit (cat. no. ab108641; Abcam), human estradiol E2 ELISA kit (cat. no. ab108640; Abcam), human testosterone ELISA kit (cat. no. ab174569; Abcam), human prolactin ELISA kit (cat. no. ab108655; Abcam), human progesterone ELISA kit (cat. no. ab108654; Abcam), human adrenocorticotropic hormone ELISA kit (cat. no. ENZ-KIT138-0001; Enzo Life Sciences, Inc., Farmingdale, NY, USA), human triiodothyronine ELISA kit (cat. no. ab108664; Abcam), human thyroxine ELISA kit (cat. no. ab108686; Abcam), human thyroid stimulating hormone ELISA kit (cat. no. ab108659; Abcam) and human parathyroid hormone ELISA kit (cat. no. ab230931; Abcam). The retina was examined using routine funduscopic examination; the reflexes of the two legs were detected using electromyography; and the brain structure was examined using MRI. The results of MRI were analyzed using fluid-attenuated inversion recovery (21). And the middle cerebral artery was examined using magnetic resonance angiography (22).

Whole exome sequencing

Genomic DNA was isolated from peripheral blood leukocytes (1 ml per patient). The whole exome was captured using a Sure Select Human All Exon kit (Agilent Technologies, Inc., Santa Clara, CA, USA), and was sequenced on an Illumina HiSeq2500 instrument (Illumina, Inc., San Diego, CA, USA). The sequenced reads were aligned to the human genome reference (University of California Santa Cruz hg 19 version; www.epigenomebrowser.org/index.html) using the Burrows-Wheeler Aligner (bwa-0.7.17) (23). Read qualities were recalibrated using the Genome Analysis Toolkit (GATK-4.0.2.1; Broad Institute, Cambridge, MA, USA). The GATK IndelRealigner was used to realign reads around insertion/deletion sites. The single nucleotide variants (SNVs) and small insertions and deletions (InDels) were generated with the GATK Unified Genotyper in parallel with the SAMtools (samtools-1.7; www.htslib.org/doc/samtools.html) pipeline. ANNOVAR (version 2.3.1) (24) was used to annotate the detected variations. ExAC (version 0.3.1; exac.broadinstitute.org) and 1,000 Genomes (www.internationalgenome.org) (25) were used to identify the population frequencies of mutations.

Deleterious missense SNVs were predicted using the following tools: i) SIFT [sift.jcvi.org; a single nucleotide polymorphism (SNP) with SIFT score <0.05 predicts a negative effect on the encoded amino acid]; ii) Polyphen2 (genetics.bwh.harvard.edu/pph2; a SNP with score between 0.85–1.0 may be predicted to be damaging to the encoded amino acid, while a SNP with score of 0.0–0.15 may be predicted to be benign, and a SNP with score of 0.15–1.0 predicts possible damage); iii) MutationTaster (www.mutationtaster.org; a score close to 1 indicates the given variant to be disease-causing); iv) MutationAssessor (mutationassessor.org/r3; High/Medium means functional and Low/Neutral means non-functional); and v) Combined Annotation Dependent Depletion (CADD; cadd.gs.washington.edu), in which a scaled CADD score of 20 means that a variant is among the top 1% of deleterious variants in the human genome, and a scaled CADD score of 30 means that the variant is in the top 0.1% (26).

Polymerase chain reaction (PCR)-sanger sequencing

PCR was used to amplify the exons containing the PNPLA6 variants identified in the whole exome sequencing. PCR was performed in a total volume of 20 µl with 50 ng genomic DNA as template, 10 µl 2X Taq Mastermix (E005; Novoprotein Scientific, Inc., Summit, NJ, USA), 1 µl forward primer (10 µmol/ml) and 1 µl reverse primer (10 µmol/ml) under the following thermocycling conditions: 94°C for 2 min; followed by 40 cycles of 94°C for 20 sec, 65°C for 20 sec and 72°C for 45 sec; and a final extension step at 72°C for 5 min. The amplified products were used for Sanger sequencing as performed by BioSune Biotechnology Co. (Shanghai, China). The sequencing results were analyzed by using DNA Star-Megalign software (version 3.3.8; DNASTAR, Inc., Madison, WI, USA). The primers used for PCR were as follows: PNPLA6-E29-forward (F), 5′-CAGGCTGTGTGTGGCGTTACGTC-3′; PNPLA6-E29-reverse (R), 5′-GCACATGTCGCTGTCCACAGGCAC-3′; PNPLA6-E30-F, 5′-GGACATCGCCCGCAGCATG-3′; and PNPLA6-E30-R, 5′-ATAGATCTGGTCGAACTTCCCAAAG-3′.

Structural modeling of proteins

Structural modeling was performed using I-TASSER (zhanglab.ccmb.med.umich.edu/I-TASSER). The models were visualized using PyMOL (version 0.99; DeLano Scientific LLC., Palo Alto, CA, USA).

Results and Discussion

Endocrine manifestation

The proband is a 39-year-old male (as of 2016). He was diagnosed with hypogonadotropic hypogonadism 25 years ago at the age of 14 years. He was subsequently treated intermittently for 2 years with testosterone, human chorionic gonadotropin and human menopausal gonadotropin, leading to significant growth in the testes and penis. The proband was married 6 years ago, although he experienced poor sexual performance and the wife of the proband did not conceive. In 2015, the proband was enrolled at The People's Hospital of Henan Province due to infertility.

As illustrated in Table I, the luteinizing hormone (LH), follicle-stimulating hormone (FSH) and testosterone levels of the proband were below normal, whereas the levels of adrenocorticotropic hormone, cortisol and thyroid hormones were in the normal range. A gonadotropin-releasing hormone (GnRH) stimulation test was additionally performed. As exhibited in Table I, GnRH failed to induce an obvious increase in FSH and LH.

Table I. Baseline hormonal profile and results of gonadotrophin releasing hormone stimulation test.

Table I.

Baseline hormonal profile and results of gonadotrophin releasing hormone stimulation test.

	Time, min
Hormone	0	30	60	90	120	Normal range, basal
LH	0.27	0.59	0.59	0.48	0.57	1.2–8.6 mIU/ml
FSH	1.97	1.07	1.69	1.87	1.81	1.3–19.3 mIU/ml
E2	38.32					<53 pg/ml
T	2.9					1.75–7.81 ng/ml
PRL	5.41					2.64–13.13 ng/ml
P	0.32					0.1–0.84 ng/ml
Cortisol
08.00 a.m.	8.60					5–25 µg/dl
04.00 p.m.	5.76					2.5–12.5 µg/dl
12.00 a.m.	<1.0					2.9–13 µg/dl
ACTH
08.00 a.m.	29.8					12–46 pg/ml
04.00 p.m.	22.8					6–23 pg/ml
FT3	5.06					3.5–6.5 pmol/l
FT4	14.34					11.5–22.7 pmol/l
TSH	1.217					0.55–4.78 µIU/ml
PTH	71.3					12–88 pg/ml

[i] LH, luteinizing hormone; FSH, follicle-stimulating hormone; E2, estradiol; T, testosterone; PRL, prolactin; P, progesterone; ACTH, adrenocorticotropic hormone; FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyroid stimulating hormone; PTH, parathyroid hormone.

Retinal degeneration and cerebellar atrophy

In a routine funduscopic examination, bilateral macular pigment epitheliopathy was identified in the proband (Fig. 1A). Therefore, it was hypothesized that the proband may be affected by BNS.

Figure 1. MRI, EMG and funduscopic examination of the proband (II:2). (A) The funduscopic examination demonstrated macular pigment epitheliopathy. (B) EMG illustrated the absence of H-reflection in both legs of the proband. (C) MRI demonstrated marked cerebellar atrophy. The (a) axial T1WI, (b) axial T2WI, and (c) axial fluid-attenuated inversion recovery demonstrated widening of the cerebellar sulci with increased cerebrospinal fluid (indicated by the yellow arrows). (d) Sagittal T1WI demonstrated the widening of cerebellar sulci (indicated by the yellow arrow) and shrinking of pituitary (arrowhead). (D) The axial T1WI (a) and axial T2WI (b) demonstrated the expansion of right lateral side (indicated by the yellow arrows). (c) Magnetic resonance angiography demonstrated a reduction in the branches of right middle cerebral artery (indicated by the yellow arrow). MRI, magnetic resonance imaging; EMG, electromyography.

The proband did not exhibit obvious gait ataxia; however, gait ataxia in patients with BNS may manifest as late as the age of 50 years (9). Therefore a thorough neurological examination was performed. No defect was detected in electroencephalography and hearing tests (data not shown). However, the proband presented with subtle defect in the finger-naseversch and alternate motion tests. In addition, the proband exhibited cavus and a reduced tendon reflex.

Electromyography demonstrated the absence of H-reflection in both legs of the proband (Fig. 1B). MRI demonstrated marked cerebellar atrophy, with widened cerebellar sulci and increased cerebrospinal fluid (Fig. 1C). Furthermore, MRI illustrated a reduction in the size the pituitary, the expansion of the right lateral side, and a reduction in the branches of the right middle cerebral artery (Fig. 1C and D). From these results, the proband was diagnosed as having BNS.

Whole exome sequencing

To understand the genetic mechanism, whole exome sequencing of the proband was performed. A total of 39.81 million clean reads were obtained following the removal of low-quality reads and adaptor or contaminant sequences. A total of 98.94% of the exome regions were covered. The sample had an average of 46.8-fold coverage of the entire exon region, of which 93.9, 80.6 and 64.4% of the targeted regions were covered at least 10, 20 and 30 times, respectively. Using the GATK, a total of 21,797 coding SNVs and 584 small indels were identified. These included 10,054 missense variants, 73 nonsense variants, 189 splice site variants and 322 frame-shift indel mutations.

Compound heterozygous mutation in PNPLA6

A total of two PNPLA6 mutations (c.3386G>T, p.G1129V and c.3534G>C, p.W1178C; Fig. 2A and B) were identified. To determine whether the two PNPLA6 mutations (c.3386G>T, p.G1129V; c.3534G>C, p.W1178C) were located in the same or different chromosomes, the mutations were analyzed in the parents of the proband. As exhibited in Fig. 2A and B, the proband inherited PNPLA6 (c.3534G>C, p.W1178C) and PNPLA6 (c.3386G>T, p.G1129V) from his father and mother, respectively. Therefore, the PNPLA6 mutations exist in a compound heterozygous form.

Figure 2. Identification of PNPLA6 mutations in the patient. (A) The pedigree of the family. Subjects in the family are identified by the Roman and Arabic numerals below the symbol, in which the Roman numerals denote the generations. Open symbols, unaffected; filled symbols, affected; squares, male; circles, female; arrow, the proband. (B) Sanger sequencing of codons 3,376–3,396 and 3,524–3,544 of the PNPLA6 genes from the proband (II:2), his father (I:1) and mother (I:2), and a wild-type control. K represents G or T; S represents G or C. (C) Schematic diagram of PNPLA6 protein. The G1129V and W1178C mutations identified in the present study are indicated with arrows. (D) The prediction of PNPLA6 mutations using SIFT, Polyphen2, MutationTaster, MutationAssessor and CADD. (E) Conservative analysis of the glycine 1,129 and tryptophan 1,178-containing portions of the PNPLA6 protein. The glycine 1,129 and tryptophan 1,178 are highlighted. PNPLA6, patatin-like phospholipase domain containing 6; Crp, cAMP-binding domain of CRP.

The PNPLA6 (c.3386G>T, p.G1129V) and PNPLA6 (c.3534G>C, p.W1178C) mutations were located in the 29th and 30th exons, respectively. The two mutations were located in the phospholipid esterase domain of the PNPLA6 protein (Fig. 2C), and were predicted to be pathologically damaging using SIFT, Polyphen2, MutationTaster, MutationAssessor and CADD (Fig. 2D). Neither PNPLA6 (c.3386G>T, p.G1129V) nor PNPLA6 (c.3534G>C, p.W1178C) were identified in the ExAC and 1,000 Genomes databases. Glycine 1,129 and tryptophan 1,178 are evolutionarily conserved (Fig. 2E). Structural modeling was additionally performed using I-TASSER (27). As exhibited in Fig. 3, mutations led to conformational alterations in the PNPLA6 protein. The overall conformation of W1178C PNPLA6 only demonstrated a minor alteration compared with wild-type (WT) PNPLA6, while the overall conformation of G1129V PNPLA6 was markedly altered (Fig. 3A). Glycine 1,129 formed a hydrogen bond with aspartic acid at 1,125 in WT PNPLA6; however, a G1129V mutation led to an alternative hydrogen bond between valine 1,129 and aspartic acid at 1,128 (Fig. 3B). Tryptophan 1,178 formed hydrogen bonds with serine 1,175 and leucine 1,174 in WT PNPLA6, whereas cysteine 1,178 only formed a hydrogen bond with leucine 1,174 in W1178C PNPLA6 (Fig. 3C).

Figure 3. Structural modeling of WT and mutant (G1129V, W1178C) PNPLA6 proteins using I-TASSER. The models were visualized in PyMOL. (A) The three-dimensional structures of WT and the respective PNPLA6 mutant. (B) The structures of amino acids 1,089–1,165 from WT and G1129V PNPLA6. (C) The structures of amino acids 976–1,375 from WT and W1178C PNPLA6. Red line, hydrogen bond. WT, wild type PNPLA6, patatin-like phospholipase domain containing 6.

PNPLA6 mutations have been identified in a panel of disorders, including Boucher-Neuhäuser syndrome, Gordon Holmes syndrome, spastic paraplegia type 39, Oliver-McFarlane syndrome and Laurence-Moon syndrome, with partly distinct and partly overlapping clinical phenotypes. For instance, Boucher-Neuhäuser syndrome and Gordon Holmes syndrome cause cerebellar ataxia and hypogonadotropic hypogonadism. However, Boucher-Neuhäuser syndrome additionally presents with chorioretinal dystrophy, whereas Gordon Holmes syndrome leads to brisk reflexes. By contrast, spastic paraplegia type 39 exhibits upper motor neuron involvement, peripheral neuropathy, and sometimes reduced cognitive functioning and/or cerebellar ataxia; Oliver-McFarlane syndrome exhibits trichomegaly, chorioretinal dystrophy, short stature, intellectual disability and hypopituitarism; and Laurence-Moon syndrome is characterized by chorioretinopathy, pituitary dysfunction, childhood onset of ataxia, spastic paraplegia and peripheral neuropathy (16,28).

PNPLA6-associated disorders are usually diagnosed by clinical and neuroimaging results combined with biallelic pathogenic variants in PNPLA6. The mutations identified in patients with PNPLA6-associated disorders (12,13,28–30) are illustrated in Fig. 4. The majority of the mutations were located in the phospholipid esterase domain of the PNPLA6 protein, although there was no disease-specific bias in these mutations. Hufnagel et al (28) envisioned that various PNPLA6 mutations may lead to different activity alterations in the neuropathy target esterase, and more severe reductions may cause more severe and early-onset presentations. However, further studies in animal models are required to uncover why mutations in one gene (PNPLA6) lead to various clinical presentations in different cell types.

Figure 4. Mutations identified in patients with patatin-like phospholipase domain containing 6-related disorders. The biallelic variants from each patient are marked with the same color. Crp, cAMP-binding domain of CRP.

In conclusion, the first BNS patient from China was identified in the present study. Although the proband did not exhibit gait ataxia at the age of 39 years old, MRI examination clearly indicated cerebellar atrophy. Genetic analysis confirmed the clinical manifestation. The present study implied that whole exome sequencing may be used for correct diagnosis and proper genetic counseling prior to the occurrence of obvious symptoms.

Acknowledgements

Not applicable.

Funding

The present study was financially supported by the National High-tech R&D Program (grant no. 2015AA020502), National Basic Research Program of China (grant no. 2012CB517904), National Natural Science Foundation of China (grant nos. 31371187, 31501152, 31401218, 81770780 and 81728013), the Basic and Frontier Project from the Department of Science, Technology of Henan Province (grant no. 142300410071) and the Fundamental Research Funds for the Central Universities of Central South University (grant nos. 1053320170642, 1053320171214 and 1053320170804).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

RZ, YZ, WHL and JDL conceived the study. RZ, YW, JLL, ZLZ and DNC recruited the patients. YZ, JW and JDL performed the experiments. RZ, YZ, JW, YW, JLL, ZLZ, XTZ, DNC, WHL and JDL analyzed the data. YZ and JDL wrote the manuscript.

Ethics approval and consent to participate

Written informed consent was obtained. The present study was approved by the ethics committees of Central South University and the People's Hospital of Henan Province.

Consent for publication

Patients provided written informed consent for the use of data in this study.

Competing interests

The authors declare they have no competing interests.

References